MétaCan
Menu
← Back to cohort

Anti-TNF Dose Augmentation Frequently Occurs in the Absence of Objective Evidence of Disease Activity: Fellows-in-Training Award (IBD Category)

2018· article· en· W2921455509 on OpenAlexaffabout
Evan Elias, Adebanke Oketola, Harminder Singh, Charles Bernstein, Laura E. Targownik

Bibliographic record

VenueThe American Journal of Gastroenterology · 2018
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicInflammatory Bowel Disease
Canadian institutionsUniversity of Manitoba
Fundersnot available
KeywordsMedicineCalprotectinInternal medicineFaecal calprotectinDemographicsDiseaseInflammatory bowel diseaseGastroenterologyDosing

Abstract

fetched live from OpenAlex

Introduction: Anti-TNF dose is frequently increased or dosing interval shortened in IBD subjects with persistent gastrointestinal symptoms. Evidence supporting dose augmentation is of low quality and the practice imparts a significant additional cost of care. Persons with symptoms ascribed to IBD may not have evidence of ongoing inflammation and therefore would not be expected to benefit from dose augmentation. We sought to determine the extent to which clinicians routinely assessed the presence of active inflammation prior to undertaking anti-TNF dose augmentation. Methods: Medical records of all IBD patients prescribed anti-TNF therapy from 2007-2016 by 8 of 23 Manitoba gastroenterologists were reviewed and demographics, disease characteristics, and IBD treatments recorded. Patients who underwent anti-TNF dose augmentation were further reviewed for the presence of objective assessment of inflammation - including laboratory investigations (CRP, ESR, albumin, ferritin, hemoglobin, fecal calprotectin), cross-sectional abdominal imaging, and endoscopy - in the 90 days preceding dose augmentation. Results: 529 subjects receiving anti-TNF therapy were identified, of whom 151 had anti-TNF doses augmented on 195 occasions (117 CD, 34 UC). 51 subjects (43.6%) with CD had penetrating disease while 16 (47.1%) with UC had pancolitis. Mean age at diagnosis was 25.5 years and 50.3% of subjects were female. There was no difference in demographics, disease phenotype, or baseline lab values between those who received dose augmentation and those who did not. Biochemical evidence of inflammation was assessed prior to dose augmentation on 134 of 195 occasions (68.7%). Results of these investigations were abnormal in only 23 cases (11.8%). Cross-sectional imaging was performed in 11 cases (5.6%) and revealed active disease in 8 (4.1%). Endoscopy was performed on 28 occasions (14.4%) with 24 (12.3%) revealing active disease. Overall, objective evidence of inflammation was present for 48 of 195 dose augmentation events (24.6%), no evidence of inflammation was present for 95 (48.7%), and no investigations were performed for 52 (26.7%). Conclusion: Anti-TNF dose augmentation routinely occurs in the absence of objective evidence of active inflammatory disease. This represents a target for ongoing quality improvement to optimize care of persons with IBD requiring anti-TNF based therapies given the significant economic burden of unjustified and potentially unnecessary dose augmentation.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.003
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.005
Threshold uncertainty score0.017

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.003
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0010.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0050.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.018
GPT teacher head0.290
Teacher spread0.273 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2018
Admission routes2
Has abstractyes

Explore more

Same venueThe American Journal of Gastroenterology→Same topicInflammatory Bowel Disease→French-language works237,207→